EUCTR2017-002060-40-Outside-EU/EEA进行中（未招募）1 期
A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in Children with Asthma (6 to Less Than 12 Years of Age)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a. Written informed consent (signed and dated) is provided by parent(s)/guardian(s) (in accordance with local regulations) before conducting any study-related procedure. Written informed assent is to be provided by children.
- •b. The patient has a body weight within 2 standard deviations (SDs) from the mean for their age and sex.
- •c. The patient is 6 to less than 12 years old with a current diagnosis of asthma.
- •d. The patient has been taking an inhaled corticosteroid or leukotriene inhibitor (eg, montelukast) for at least 30 days prior to screening. Patients are allowed to be on additional asthma controllers (eg, long acting ß-agonist).
- •e. The patient is in otherwise good health (except for the diagnosis of asthma).
- •f. The patient has a blood eosinophil level of at least 150 x 106/L at screening.
- •g. Female patients who are postmenarche or sexually active must have a negative pregnancy test result, must have exclusively same sex partners or be using a highly effective method of birth control, and must agree to continued use of this method for 30 days prior to the study, for the duration of the study, and for 5 months after the dose of study drug. Highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate (ie, <1% per year) when used consistently and correctly. Highly effective methods of birth control in this study include: combined (estrogen and progestogen containing) or progestogen only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone releasing system, bilateral tubal occlusion, vasectomized partner, and sexual abstinence.
- •h. The patient has negative alcohol test and urine drug screen (UDS) results. A positive UDS result with appropriate medical explanation may be permitted after consultation with the medical monitor.
- •I. The patient and parent(s)/guardian(s) are willing and able to comply with all study restrictions, perform required procedures, report to the study center for the required visits and remain at the study center for the required durations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 36
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •a. The patient has any clinically significant medical history or current uncontrolled medical condition (treated or untreated) that would interfere with the study schedule or procedures, interpretation of results, or compromise the patient’s safety. This includes clinically uncontrolled asthma, in the judgment of the investigator.
- •b. The patient is anemic (hemoglobin c. The patient has known hypereosinophilic syndrome.
- •d. The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis eosinophilic granulomatosis with polyangiitis [also known as Churg-Strauss syndrome], allergic bronchopulmonary aspergillosis, or autoimmune disease).
- •e. The patient has a history of near-fatal asthma (an episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures) at any time in the past.
- •f. The patient is currently using any systemic immunosuppressive treatment or immunomodulatory biologic (eg, anti-IgE monoclonal antibody, other monoclonal antibodies or soluble receptors), non biologic (eg, methotrexate, cyclosporine, or maintenance oral corticosteroids), or allergen immunotherapy.
- •g. The patient has received an investigational drug within 30 days or 5 half-lives prior to the dose of study drug. For a new chemical entity or biologic product, the patient has received the product within 3 months or 5 half-lives prior to the dose of study drug, whichever is longer.
- •h. The patient has a positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus.
- •i. The patient has an active helminthic parasitic infection or was treated for one within 6 months prior to screening. Patients who live with anyone that currently has a helminthic parasitic infection or was treated for one within 6 months are also excluded.
- •j. The patient has a known or suspected hypersensitivity or idiosyncratic reaction to anti interleukin 5 (anti-IL-5) antibodies, any compound present in the study drug, or monoclonal antibodies.
- •k. The patient has previously been exposed to reslizumab or any other anti IL 5 treatment.
- •l. The patient is, in the opinion of the investigator or designee, considered unsuitable or unlikely to comply with the study protocol for any other reason.
研究者
相似试验
进行中（未招募）
不适用
Study to investigate the effect of liver impairment on the way the body eliminates the drug BAF312 in patients with mild, moderate and severe liver impairment compared to healthy persons.subjects with mild (Group 1), moderate (Group 2), and severe (Group 3) hepatic impairment.EUCTR2012-000562-37-HUovartis Pharma Services AG48
进行中（未招募）
不适用
A study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjectsMild and moderate hepatic impairmentMedDRA version: 14.1Level: PTClassification code 10024670Term: Liver disorderSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2012-000983-27-DEovartis Pharma Services AG32
招募中
1 期
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964)Healthy Adult ParticipantsCTIS2022-502952-30-00Janssen - Cilag International32
进行中（未招募）
1 期
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic functioActivated Phosphoinositide 3-Kinase Delta SyndromeMedDRA version: 20.0Level: PTClassification code: 10078281Term: Activated PI3 kinase delta syndrome Class: 100000004850CTIS2023-508519-22-00Pharming Technologies B.V.32
已完成
不适用
An open-label, parallel-group, single-dose study to evaluate the absolute bioavailability and tolerability of subcutaneous UCB4940 in healthy subjectsrheumatoid arthritisNL-OMON41792CB Celltech30